Cirugía en medicina general: manual de enfermedades quirúrgicas

296 Cirugía en Medicina General Burgos, L. (2008). Colangiocarcinoma. Actualización, diagnóstico y terapia. Revista médica de Chile, 240-248. Cammà, C., Schepis, F., Orlando, A., Albanese, M., Shahied, L., Trevisani, F., . . . Cottone, M. (2002). Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology, 47-54. Carr, B. (2016). Tumors of the liver and biliary tree. En D. Kasper, A. Fauci, S. Hauser, .. Longo, J. Jameson, & J. Loscalzo, Harrison. Principios de Medicina Interna. McGraw-Hill. Chapman, W., Majella Doyle, M., Stuart, J., Vachharajani, N., Crippin, J., Anderson, C., . . . Brown, D. (2008). Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Annals of surgery, 617-625. Chen, M., Li, J., Zheng, Y., Guo, R., Liang, H., Zhang, Y., . . . Lau, W. (2006). A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Annals of surgery, 321- 328. Cheng, E., Zarrinpar, A., Geller, D., Goss, J., & Busuttil, R. (2015). Liver. En C. Brunicardi, D. Andersen, T. Billiar, D. Dunn, J. Hunter, J. Matthews, & R. Pollock, Schwartz ´s Principles of Surgery. New York: McGraw-Hill. Cicalese, L., & Talavera, F. (2019). Hepatocellular Carcinoma. Medscape. Del Pozo, A., & López, P. (2007). Management of hepatocellular carcinoma. Clinics in liver disease, 305-321. Fava, M., Meneses, L., Gonzalez, R., & Loyola, S. (2008). Quimioembolización hepática en el manejo terapéutico del hepatocarcinoma. Reporte de dos casos. Revista médica de Chile, 496-501. Figueras, J., Ibañez, L., Ramos, E., Rafecas, A., Fabregat, J., Torras, J., & Jaurrieta, E. (2002). La resección es un buen tratamiento del hepatocarcinoma sobre el hígado cirrótico en pacientes seleccionados. Revista de cirugía española, 28-33. Folprecht, G., Gruenberger, T., Bechstein, W., Raab, H., Lordick, F., Hartmann, J., . . . Köhne, C. (2010). Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. The Lancet, oncology, 38-42. Goldaracena, N., Gorgen, A., & Sapisochin, G. (2018). Current status of liver transplantation for cholangiocarcinoma. Liver transplantation, 294-303. Hashem, B. (2011). Hepatocellular Carcinoma. New England Jurnal of Medicine, 1118-1127. Hyo Jung, K., Jae, K., Moon, J., Beom, J., Ji, K., Jong, Y., . . . Young-Tae, B. (2015). Hepatolithiasis and intrahepatic cholangiocarcinoma: A review. World journal of gastroenterology, 13418-13431. Ibrahim, S., Roychowdhury, A., &Hean, T. (2007). Risk factors for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. The American Journal of Surgery, 17-22. Ito, K., Govindarajan, A., Ito, H., & Fong, Y. (2010). Surgical treatment of hepatic colorectal metastasis: evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century. Cancer journal, 103-110. Kim, R., Reed, A., Fujita, S., Foley, D., Merkeel, K., & Hemming, A. (2007). Consensus and controversy in the management of hepatocellular carcinoma. Journal of the American College of Surgeons, 108-123. Komorizono, Y., Oketani, M., Sako, K., Yamasaki, N., Shibatou, T., Maeda, M., . . . Arima, T. (2003). Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer, 1253-1262. Krasinskas, A. (2018). Cholangiocarcinoma. Surgical pathology clinics, 403-429. Lai, E., Tang, C., Ha, J., Tsui, D., & Li, M. (2008). Cytoreductive surgery in multidisciplinary treatment of advanced hepatocellular carcinoma. ANZ journal of surgery, 504-507. Lam, V., Ng, K., Chok, K., Cheung, T., Yuen, J., Tung, H., . . . Poon, R. (2008). Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. Journal of the American College of Surgeons, 20-29. Li, L., Zhao, W., Wang, M., Hu, J., Wang, E., Zhao, Y., & Liu, L. (2018). Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. BMC gastroenterology, 138-149. Livrahi, T. (2003). Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma. Journal of hepato-biliary- pancreatic surgery, 67-76. Llovet, J., & Bruix, J. (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 429-442. Llovet, J., & Bruix, J. (2008). Novel advancements in the management of hepatocellular carcinoma in 2008. Hepatology, 20-37. Llovet, J., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J., . . . group, S. i. (2008). Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 378-390. Mazzaferro, V., Rondinara, G., Rossi, G., Regalia, E., De Carlis, L., Caccamo, L., . . . Armiraglio, E. (1994). Milan multicenter experience in liver transplantation for hepatocellular carcinoma. Transplantation proceedings, 3557-3560. Mulier, S., Mulier, P., Ni, Y., Miao, Y., Dupas, B., Marchal, G., . . . Michel, L. (2002). Complications of radiofrequency coagulation of liver tumours. British journal of surgery, 1206-1222. Nagano, Y., Togo, S., Tanaka, K., Masui, H., Endo, I., Sekido, H., . . . Shimada, H. (2003). Risk factor and management of bile leakage after hepatic resection. World Journal of Surgery, 695-